

**REMARKS**

Claims 10, 11, 179, 181, 182, and 187-196 are pending in the application. By this amendment, claims 10, 11 and 189 are amended. Following entry of this amendment, claims 10, 11, 179, 181-182 and 187-196 will be pending. Support for the amended claims is found throughout the specification and originally filed claims, including, e.g., at page 94, line 12; 75, lines 15-16. No new matter is added by this amendment. Entry of this amendment is respectfully requested.

With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter and moreover have not acquiesced to any objection and/or rejection made by the Office. Applicants expressly reserve the right to pursue prosecution of any subject matter not presently claimed in one or more future or pending continuation and/or divisional applications.

Applicant acknowledges the withdrawal of the prior rejections under 35 USC §112.

***Rejection Under 35 U.S.C. § 112, second paragraph***

Claims 10, 11, 189 and their dependent claims 179, 181-182, 187-188 and 190-196 are rejected as allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants respectfully traverse this rejection. Applicants respectfully disagree that the phrase “modulate hepatocellular carcinoma” is indefinite, as stated in the Office Action. However, claims 10, 11 and 189 are amended and now recite “modulate hepatocellular carcinoma development” as suggested by the Examiner. Withdrawal of this rejection is respectfully requested.

**SUMMARY**

Applicants believe that this application is now in condition for allowance and respectfully requests that the outstanding rejections be withdrawn and this case passed to issue. The Examiner is invited to contact the undersigned at (650) 467-6222 in order to expedite the resolution of any remaining issues.

In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account **07-0630** for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Respectfully submitted,  
GENENTECH, INC.

Date: 7-13-07

By: Cara Coburn  
Cara Coburn  
Reg. No. 46,631  
Telephone No. (650) 467-6222